CLINICAL_TRIALS
trial_result
· 2023-05-12
Clinical Trial Update: P3 Long Term Safety Study of Once Daily SB204 in Acne [Phase 3]
Summary
Phase 3 long-term safety study of once-daily SB204 in acne vulgaris completed; results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Novan, Inc. | Conditions: Acne Vulgaris | Phase 3 | Status: COMPLETED | Results posted: 2023-05-12